11.21
+0.01(+0.09%)
Currency In USD
| Previous Close | 11.2 |
| Open | 11.11 |
| Day High | 11.38 |
| Day Low | 10.96 |
| 52-Week High | 24.17 |
| 52-Week Low | 9.68 |
| Volume | 411,978 |
| Average Volume | 1.19M |
| Market Cap | 871.73M |
| PE | -4.77 |
| EPS | -2.35 |
| Moving Average 50 Days | 16.91 |
| Moving Average 200 Days | 19.71 |
| Change | 0.01 |
If you invested $1000 in Kura Oncology, Inc. (KURA) since IPO date, it would be worth $747.33 as of December 03, 2024 at a share price of $11.21. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $730.29 as of December 03, 2024 at a share price of $11.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology to Host Virtual Investor Event on December 9, 2024
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASHSAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical compan
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
GlobeNewswire Inc.
Nov 25, 2024 12:30 PM GMT
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
GlobeNewswire Inc.
Nov 20, 2024 10:00 PM GMT
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomeni